Efficacy and Safety of Silfamin for Common Cold

Summary

This is a 2-arm, prospective, randomized, double-blind, placebo-controlled, and three-days-treatment clinical study comparing the efficacy and safety of Silfamin at a dose of 2 tablets@150 mg twice daily in subjects with common cold.

Timeline

Start

2024-07-12

Primary completion

2024-09-30

Completion

2024-09-30

Drugs

Indications